Changes in executives of well-known multinational arms companies.

On September 15th, according to Wallian Medical, Valian's new position as global president and chief operating officer will be filled by Chris Toth, the current president of Wallian Oncology Systems.
O'Reilly, senior vice president of global operations at the Company, will replace Taukry as president of Wallian Oncology Systems.
, Vice President of Revenue Operations, will be appointed Senior Vice President for Global Supply Chain Operations.
management appointment will take effect on 5 October 2020.
has nearly 20 years of industry experience and has held a number of management positions since joining Valian in 2001, according to a medical officer at the company.
currently president of Valian Oncology Systems, managing more than $3 billion in business and more than 7,000 employees worldwide.
in this position, Taukry helped Wallian recover double-digit growth.
in this role, he was President of Wally's Safeball Business and Field Operations, responsible for global sales strategy and execution for Valian's oncology and proton therapy business.
Kevin O'Reilly has over 30 years of cross-industry, cross-regional management experience.
is currently Senior Vice President of Wally's Safety Ball Operations, responsible for Wally's Global Supply Chain, Revenue and Customer Support, managing $3 billion in revenue and more than 2,000 employees worldwide.
, he served as President of Wallian Asia Pacific before joining Valian in 2009, where he held management positions at RPO, Inc. and Photon Dynamics.
Stephanie Foster currently serves as Vice President of Revenue Operations, managing contracts, sales and operations planning, logistics, installation services, and environmental health and safety.
she joined Valian in 2019, she was Vice President of Honeywell Supply Chain, managing approximately $4 billion in revenue from the business unit that manufactures products for the defense, aerospace and aerospace industries.
before joining Honeywell, she held management positions at OrbitalATK and Raytheon.
2020: Siemens' acquisition of Valian is notable for the fact that, 45 days before this major personnel change, on August 2, Siemens Medical and Valian Medical Systems announced that they had signed an agreement to acquire all shares of Valian Medical Systems for $177.50 per share in cash, for a total price of approximately $16.4 billion, or about RMB114.38 billion.
Siemens Medical's acquisition of Valian is expected to be completed in the first half of 2021 and will eventually be subject to approval by Valian shareholders and regulators, as well as other agreed acquisition conditions.
said it expects to continue operating as an independent company within Siemens Medical under the Valian brand after the deal is completed.
combined company will provide a fully integrated platform covering end-to-end oncology solutions to ensure the full continuity of cancer care: from screening and diagnosis to treatment care to post-treatment survival.
understood that Valian, medical science, Ancory is known in the industry as the radiotherapy industry's three giants.
Valian's market share may have been the largest of the big three - in 2018, according to Valian's financial results, it has a global market share of more than 50 per cent and a 40 per cent chinese market share, while Medical Anda and Siemens are in second and third place with 32.8 per cent and 14.3 per cent respectively.
Valian's current main business is divided into imaging originals and oncology systems (radiation therapy), according to Siyu Medical Watch combing, Valian imaging business sales in the world ranked 10th, which accounts for only 20% of its total business share.
accounts for about 75% of its cancer radiotherapy market and 70% of the global radiotherapy market, with cancer system products accounting for about 45% and oncology system services accounting for about 30%.
valiant revenue for the six months to April 3 was $828 million, essentially the same as in the same period in 2019, according to the latest financial results.
.